Inclusion Criteria:

- Histologically documented synovial sarcoma

- RECIST measurable metastatic or locally recurrent disease who have failed standard
treatment

- Expected survival of at least 6 months

- Weight at least 25 kg

- ECOG performance scale 0-2

- At least 3 weeks since major surgery, and at least 3 weeks since completing radiation
therapy or chemotherapy (6 weeks for patients receiving mitomycin)

- Resolution of toxicity from previous treatment to NCI-CTC grade 1 or less before
treatment

- Adequate bone marrow, renal and hepatic function

- Age at least 13 years

- Able and willing to give valid written informed consent

Exclusion Criteria:

- Clinically significant heart disease (NYHA Class III or IV)

- Other serious illnesses, e.g. serious infections requiring antibiotics or bleeding
disorders

- History of autoimmune disease

- Patients with a second cancer diagnosis in the last five years, except for basal cell
carcinoma, completely resected, or cervical carcinoma in situ (CIN), completely
resected

- Known HIV positivity

- Metastatic disease to the central nervous system for which other therapeutic options,
including radiotherapy, may be available

- Chronic use of immunosuppressive drugs such as systemic corticosteroids.

- Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study

- Lack of availability for immunological and clinical follow-up assessments

- Participation in any other clinical trial involving another investigational agent
within 3 weeks prior to enrollment

- Pregnancy or breast feeding

- Refusal or inability to use effective means of contraception (all men, and women with
childbearing potential)